Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma

NCT02526823 is registered in ClinicalTrials.gov with Shandong Provincial Hospital as lead sponsor.

NCT NCT02526823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02526823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma
Lead sponsor
Shandong Provincial Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
August 31, 2015
Completion date
December 31, 2019
Enrollment
360 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non-hodgkin;hodgkin disease